| (Values in U.S. Thousands) | Jun, 2018 | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Bexil Corp (BXLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Bexil Corporation is a holding company operating businesses directly or through companies in which it has a majority or other substantial interest. It intends to acquire and/or develop one or more businesses. Bexil's preferred transaction is a management buyout. Particularly interested in a spinoff from a larger company, Bexil can provide the equity component of a leveraged buyout (LBO) financing. Based in New York, the company is evaluating opportunities to develop and acquire long-term acute care hospitals (LTACHs).